TARA-002 for Bladder Cancer

(ADVANCED-3 Trial)

This trial evaluates whether a new drug, TARA-002, can treat high-grade non-muscle invasive bladder cancer (a type of bladder cancer that hasn't spread to the muscle). It compares TARA-002 to standard intravesical chemotherapy (chemotherapy delivered directly into the bladder) to determine which is more effective and has fewer side effects. The trial includes individuals who have never received BCG treatment (a common bladder cancer treatment) or haven't had it in the last two years. Those with bladder cancer who haven't recently tried BCG may find this trial suitable. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.

Research has shown that TARA-002 is likely safe. Studies have found it well tolerated by patients with non-muscle invasive bladder cancer (NMIBC). Most reported side effects were mild and manageable. Various studies have tested this treatment, and most patients experienced only minor issues. This suggests that TARA-002 is generally safe for treating this type of bladder cancer.¹²³⁴⁵

Unlike the standard of care for bladder cancer, which typically involves intravesical chemotherapy, TARA-002 is unique because it utilizes a novel approach. TARA-002 is derived from a naturally occurring bacterium, which is designed to stimulate the immune system to target and destroy cancer cells directly in the bladder. This method can potentially enhance the body's natural defenses against cancer, offering a different mechanism of action compared to traditional chemotherapy. Researchers are excited about TARA-002 because it has the potential to provide a more targeted and possibly less toxic treatment option for patients with bladder cancer.

Research has shown that TARA-002, one of the treatments in this trial, holds promise for treating high-grade non-muscle invasive bladder cancer (NMIBC). Studies have found that about 68-72% of patients had no detectable cancer six months after treatment. After 12 months, this number remained high, with about 50-55% of patients showing no signs of cancer. TARA-002 works by directly killing cancer cells and enhancing the body's immune response against the cancer. Overall, evidence suggests that TARA-002 could be a strong treatment option for patients with this type of bladder cancer. Participants in this trial may receive TARA-002 or the investigator's choice of intravesical chemotherapy, which serves as the active comparator.¹³⁶⁷⁸